DAR-0100A

Larry J. Siever · Phase 2 active Small molecule

At a glance

Generic name	DAR-0100A
Sponsor	Larry J. Siever
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A D1 Agonist For Working Memory (PHASE2)
Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13 (PHASE1)
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders (EARLY_PHASE1)
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DAR-0100A CI brief — competitive landscape report
DAR-0100A updates RSS · CI watch RSS
Larry J. Siever portfolio CI